Second Closing of the Fundrai

RNS Number : 8902T

Synairgen plc

15 June 2009

 



15 June 2009

Synairgen plc

('Synairgen' or 'the Company')

SECOND CLOSING OF THE FUNDRAISING

Synairgen announced on 27 May 2009 its intention to raise £6.35 million (gross) by means of a placing with institutional investors of 29,499,993 new Ordinary Shares (the 'Placing') and a subscription by certain Directors and others for 7,852,948 new Ordinary Shares (the 'Subscription'), all at a price of 17p per Ordinary Share (together the 'Fundraising').

On 12 June 2009, Synairgen announced that shareholder approval of the Fundraising had been obtained and that 7,852,948 Ordinary Shares were allotted and are expected to be admitted to trading on AIM on 18 June 2009.

Synairgen today announces that the remaining 29,499,993 Ordinary Shares have been allotted. Application will be made to admit such Ordinary Shares to trading on AIM, which is expected to occur on 19 June 2009.

Following the second closing of the Fundraising, the issued share capital of Synairgen will comprise 59,745,249 Ordinary Shares. The Company holds no shares in treasury. Therefore, the total number of voting rights in the Company will be 59,745,249. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Ends

For further information, please contact:

Synairgen plc	Tel: + 44 (0) 2380 512 800
Richard Marsden, Managing Director John Ward, Finance Director
Matrix Corporate Capital	Tel: + 44 (0) 20 3206 7000
Louis Castro
Threadneedle Communications	Tel: + 44 (0) 20 7653 9850
Graham Herring Josh Royston

  Notes for Editors

About Synairgen

Synairgen is a drug discovery and development company founded by Professors Stephen Holgate, Donna Davies and Ratko Djukanovic, focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and chronic obstructive pulmonary disease (COPD). Synairgen is quoted on AIM (LSE: SNG).

Synairgen's researchers use advanced cell models incorporating human tissue and cells drawn from its biobank of clinical samples, which are obtained from well-characterised healthy control, asthma or COPD volunteers. 

Synairgen's lead programme, inhaled interferon beta for the prevention of virus-induced exacerbations of asthma and COPD, is currently undergoing its second Phase I clinical trial.

For more information about Synairgen please see www.synairgen.com.

Asthma statistics 

• There are approximately 23 million asthmatics in the USA2

• The economic cost to the USA of asthma is $19.7 billion per year3 

• Asthma accounts for 1.7 million emergency department visits per year in the USA2 

• The cost of emergency department visits and in-patient care in relation to asthma in the USA is $4.7 billion2

• The average duration of a hospitalisation for an asthma exacerbation in the USA is 2.7 days at a cost of $9,0784 

• 50% of the total cost of the asthma is apportioned to 10% of the asthmatic population with the severest disease5

COPD statistics

• COPD (chronic obstructive pulmonary disease) includes chronic bronchitis and emphysema

• COPD is forecast to be the third leading cause of death worldwide (after heart attack and stroke) by 20306

• 12 million adults in the USA have reported a physician diagnosis of COPD. However, as many as 24 million adults have some evidence of impaired lung function, implying an under-diagnosis of this disease7

• The economic cost to the USA of COPD is $42.6 billion per year3

• Hospital care cost $11.3 billion2 and in 2005 there were 721,000 hospitalizations for COPD in the USA8

Rhinovirus (common cold virus) and exacerbations (worsening of symptoms) of asthma and COPD 

• Adults get an average of two to four colds per year, mostly between September and May. Young children suffer from an average of six to eight colds per year9

• Rhinovirus infections are the major cause of asthma exacerbations, accounting for 50% to 80% of all such attacks in both children and adults10

• 80-85% of COPD exacerbations are associated with viral or bacterial respiratory tract infections with rhinovirus (common cold virus) and Haemophilus influenzae thought to be the major contributors11 

  References

• P. Wark et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus.  J Exp Med. 2005; 201: 937-947

• American Lung Association. Trends in Asthma Morbidity and Morality. January 2009 www.lungusa.org

• National Heart Lung and Blood Institute, Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases 

• V. Krishnan et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006 174, 633-638

• P.J. Barnes, B. Johnson, J.B. Klim. The Costs of Asthma. Eur Respir J 1996 9, 636-642  

• World Health Organisation website (http://www.who.int/respiratory/copd/burden/en/index.html)

• Centers for Disease Control and Prevention. National Center for Health Statistics. National Health & Nutrition Examination Survey, 1988-1994

• American Lung Association: Trends in COPD (chronic bronchitis and emphysema): Morbidity and Mortality. December 2007 www.lungusa.org

• American Lung Association: Cold and Flu Guidelines: The Common Cold www.lungusa.org

• J.T. Kelly et al. Host immune responses to rhinovirus: Mechanisms in asthma. J Allergy Clin Immunol 2008; 122: 671-682 

• A. Sethi et al. Infection in the Pathogenesis and Course of Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 2355-65 

 

END

 

 

MSCBGGDLSGBGGCU